摘要
Abstract
In recent years,ursodeoxycholic acid is commonly used for the treatment of primary biliary cholangitis (PBC);however,the growing number of PBC patients and the occurrence of suboptimal response and treatment intolerance pose a great challenge to treatment regimens.The approval of the new drug obeticholic acid brings hope to PBC patients,and a combination of fibrates also has a promising future.More studies are in progress.Although new drugs,such as monoclonal antibody,fibroblast growth factor 19,and sodium-dependent bile acid transporter inhibitor,have limited efficacy data,they provide new directions for the treatment of PBC.With the help of individualized follow-up and stratified therapy,the management of PBC patients will enter a new stage.关键词
胆管炎,胆汁性/熊脱氧胆酸/鹅脱氧胆酸/氯贝酸/糖皮质激素类/抗体,单克隆Key words
cholangitis, biliary/ursodeoxycholic acid/chenodeoxycholic acid/clofibric acid/glucocrticoids/antibodies, monoclonal分类
医药卫生
